Abstract 481: Utility of hCG as a biomarker of treatment response in advanced urothelial cancer: A population based series at Akershus University Hospital, Norway
Katarina Puco(Akershus University Hospital), Jan Oldenburg(Akershus University Hospital), Mattias Røed-Undlien(Akershus University Hospital), Haldor Husby(Akershus University Hospital), Oluf Dimitri Røe(Norwegian University of Science and Technology), Fredrik A. Dahl(Akershus University Hospital), Johan Bjerner, Gunder M. Lilleaasen(Akershus University Hospital), Daniel Heinrich(San Antonio College), Stig Müller(Akershus University Hospital)
Cited by 1
Related Papers
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial
|The Lancet Oncology|2014|491
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
|European Urology|2020|396
Testicular Cancer Survivorship: Research Strategies and Recommendations
|JNCI Journal of the National Cancer Institute|2010|289
Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma
|Journal of Clinical Oncology|2018|229